Ann: CYP-001s FDA Approval Pathway Not Impeded, page-17

The reasons are clear:

1a) solely relying on company announcement/s,
1b) with limited capacity to comprehend the content of said announcement (which is the intention as clearly displayed by the choice of words used in these announcements),
1c) and too lazy and/or perhaps simple to do their own research (I could list numerous examples, i.e. office in Ireland, cancer, EcoQuest "origin", Orphan drug designation, licence agreement with Osiris covering Prochymal - which is still in place btw until early 2026 and resulting in payments to be made on Ryoncil sales to Osiris + add to that the interest charges now payable due to Ryoncil sales and you'll see that there could be some financial restraints still on the table, etc.)
2) fear, that there could be another treatment on the horizon that may show promise in indications approved or targeted by their holding, therefore may have a negative impact on the potential return of their investment (hopefully CYP kept some of the EcoQuest nappies), and
3) boredom, as they have nothing else to do despite claims of family and friends (it can get very lonely when you are "so much better" than everyone else and whilst this is a cesspool for anonymous posters to be someone they are not in real life, certain trades displayed here are nothing doubt a reflection of their true personalities).

Anyways, enough for now, but likely more to follow, especially on points 1b and 1c.